

Accepted Manuscript


Title: Effects and Management of Denosumab Discontinuation

Author: Roland Chapurlat

PII: S1297-319X(18)30001-0

DOI: <https://doi.org/doi:10.1016/j.jbspin.2017.12.013>

Reference: BONSOI 4674



To appear in:

Received date: 7-10-2017

Accepted date: 20-12-2017

Please cite this article as: Chapurlat R, Effects and Management of Denosumab Discontinuation, *Joint Bone Spine* (2018), <https://doi.org/10.1016/j.jbspin.2017.12.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effects and Management of Denosumab Discontinuation

Roland Chapurlat^{a,b,c}

^aService de Rhumatologie et Pathologie Osseuse, Hôpital E Herriot, 69437 Lyon, cedex 03, France

^bINSERM UMR 1033, 69437 Lyon, cedex 03, France

^cUniversité de Lyon, 69437 Lyon, cedex 03, France

roland.chapurlat@inserm.fr

KEY WORDS: osteoporosis - fracture - denosumab - drug holiday

The optimal duration of the treatment of osteoporosis has remained controversial since the introduction of the first efficacious drugs - bisphosphonates - decades ago. Indeed, their antiresorptive effect may persist for several years after stopping drug exposure, due to their strong affinity to hydroxyapatite. Even if the long-term use of these drugs has been shown to be safe up to 10 years, a drug holiday after 5 years of use has been frequently advocated, despite lack of evidence both on its role in preservation of reduced fracture risk and a possibly improved safety [1]. The duration of treatment may also be decided based on patient characteristics after a few years of treatment, including the femoral neck T-score and prevalent fracture (the so-called treat-to-target or goal-directed strategy) [2].

This concept of drug holiday should not be applied to medications other than bisphosphonates, without skeletal retention, because bone loss is expected to resume and the

Download English Version:

<https://daneshyari.com/en/article/11014198>

Download Persian Version:

<https://daneshyari.com/article/11014198>

[Daneshyari.com](https://daneshyari.com)